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Chronic pain is accompanied with long-term sensory, affective and cognitive
disturbances. What are the mechanisms that mediate the long-term consequences of
painful experiences and embed them in the genome? We hypothesize that alterations
in DNA methylation, an enzymatic covalent modification of cytosine bases in DNA,
serve as a “genomic” memory of pain in the adult cortex. DNA methylation is an
epigenetic mechanism for long-term regulation of gene expression. Neuronal plasticity at
the neuroanatomical, functional, morphological, physiological and molecular levels has
been demonstrated throughout the neuroaxis in response to persistent pain, including
in the adult prefrontal cortex (PFC). We have previously reported widespread changes
in gene expression and DNA methylation in the PFC many months following peripheral
nerve injury. In support of this hypothesis, we show here that up-regulation of a gene
involved with synaptic function, Synaptotagmin II (syt2), in the PFC in a chronic pain
model is associated with long-term changes in DNA methylation. The challenges of
understanding the contributions of epigenetic mechanisms such as DNA methylation
within the PFC to pain chronicity and their therapeutic implications are discussed.
Keywords: chronic pain, epigenetics, neuropathy, prefrontal cortex, DNA methylation, synaptotagmin,
neuroplasticity

Chronic Pain is Associated with Anatomical, Morphological,
and Physiological Changes in the Adult Prefrontal Cortex
Chronic pain is associated with a multitude of co-morbidities, including depression, anxiety,
cognitive impairment, memory deficits and loss of motivation both in humans (Sharp and Keefe,
2005) and in animal models (Low, 2013; Schwartz et al., 2014; Tajerian et al., 2014). Rather than the
pain itself, these higher-order functions, mediated by supra-spinal structures, can have the biggest
impact on quality of life in chronic pain patients (Nicholson and Verma, 2004).
Chronic pain changes brain anatomy and function. Studies in rodent models of chronic
pain have demonstrated pain-related modifications in areas including the hippocampus,
amygdala, perirhinal cortex, and prefrontal cortex (PFC; Seminowicz et al., 2009; Mutso
et al., 2012; Alvarado et al., 2013; Tajerian et al., 2013, 2014). These findings extend to
humans---multiple studies have reported decreased gray matter, reduced cortical thickness,
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abnormal cortical function, and altered connectivity in various
brain regions in a wide range of chronic pain conditions
including low back pain (Giesecke et al., 2004; Apkarian
et al., 2005; Schmidt-Wilcke et al., 2006; Tagliazucchi et al.,
2010; Berger et al., 2014), headache (Schmidt-Wilcke et al.,
2005), fibromyalgia (Kuchinad et al., 2007; Schmidt-Wilcke
et al., 2007), post-stroke pain (Krause et al., 2014), complex
regional pain syndrome (Pleger et al., 2014), burning mouth
syndrome (Khan et al., 2014), and irritable bowel syndrome
(Davis et al., 2008). The magnitude of these changes has
been related to the duration and the intensity of chronic pain
(Apkarian et al., 2004).
While changes in some brain regions are associated
with specific chronic pain conditions, most studies report
changes in common areas involved in pain modulation,
including the PFC (Apkarian et al., 2009; Neugebauer
et al., 2009). Interestingly, the PFC has been implicated
in depression, anxiety and cognitive impairment, all of
which are frequently associated with chronic pain. Painrelated pathological changes in the PFC may therefore
contribute to the emergence of emotional and cognitive
impairments.
In order to determine if chronic pain could induce painrelated changes in brain anatomy, Seminowicz et al. conducted
a longitudinal study of chronic neuropathic pain in rats
(Seminowicz et al., 2009). Consistent with the human literature,
pain-related decreases in frontal cortex volume were observed
in rats subjected to peripheral nerve injury as adults. These
changes were not observed until approximately 4 months postinjury and were temporally correlated with the development of
anxiety-like symptoms in the same animals. Thus, pain-related
changes in the PFC are a consequence of chronic, but not
acute pain.
At the molecular/cellular level, animal studies have
demonstrated neuropathy-induced altered dendritic branching
and spine density. For example, basal dendrites had longer
branches in the PFC in animals with peripheral nerve injury
than in controls (Metz et al., 2009). Changes in neuroanatomy
are also linked to functional differences within the firing of
pyramidal neurons (Centeno et al., 2009; Metz et al., 2009) and
reduced connectivity between the PFC and other brain regions
(Cardoso-Cruz et al., 2013a,b).
Ongoing chronic pain not only induces changes in the
PFC but also actively maintains them. We have shown that
pathological changes in the PFC in individuals with chronic
low back pain (cLBP) can be reversed with effective pain
management (Seminowicz et al., 2011). Specifically, cLBPassociated cortical thinning in the dorsolateral PFC (DLPFC)
was reversed post-treatment, and the magnitude of this reversal
correlated with the reduction of both pain and physical
disability. Furthermore, abnormal activity in the DLPFC
during an attention-demanding cognitive task in cLBP patients
was reduced towards normal levels following treatment. The
ability of the adult PFC to undergo neuroplastic changes
is further supported by studies in healthy subjects (Hötting
and Röder, 2013). For example, increased physical activity
resulted in improved memory and increased local gray matter
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TABLE 1 | Classification of transcriptome-identified promoters.
Gene
type
Housekeeping
Weak promoter
Narrow promoter
Broad promoter
Bivalent

Number
of genes*

Differentially
expressed*

Enrichment
p-value**

Enrichment
status+

3292
5262
930
1279
3400

29
118
43
51
166

1.60E-13
0.07
1.20E-04
9.50E-04
4.90E-18

Depleted
Depleted
Enriched
Enriched
Enriched

*Considers only protein coding genes. **Enrichment was tested by Fisher’s
exact test.

+

Depleted/enriched identify cases where the number of genes is

smaller/larger than expected.

volume in the PFC in adult volunteers (Ruscheweyh et al.,
2011).
These data indicate that long-term structural and functional
brain abnormalities---specifically in the PFC---are induced by
chronic pain. Furthermore, they suggest that treating chronic
pain can restore normal brain function in the adult human PFC
and raise the possibility that therapies targeting pathological
changes in the PFC have therapeutic utility. Finally, the
reversibility suggests that these changes are unlikely to be due to
neurotoxicity; in contrast, the underlying mechanisms must be
both long-lasting and reversible.

Pain-Related Changes in Gene Expression
in the Adult Prefrontal Cortex
Given the extensive structural and functional abnormalities in
the PFC associated with pain persistent changes in genomic
programming are likely to contribute to both chronic pain
and to the associated co-morbidities. For example, in a model
of acute facial pain, genes related to immune function and
neutrophil activation are over-expressed in the PFC (Poh
et al., 2012). In chronic neuropathic pain, we observed
differential RNA expression of 1147 genes. Some of these
genes are associated with functional pathways involved in
neuronal development, cell differentiation and growth in the
PFC 6 months following peripheral nerve injury (Alvarado
et al., 2013). Furthermore, the majority of these differentially
expressed transcripts were enriched for narrow, broad and
bivalent types of promoters (Table 1, Lenhard et al., 2012).
That is, narrow and weak promoters represent tissue specific
and general cell cycle processes, respectively. This suggests that
transcriptional landscape is accompanied with changes that
are enriched for tissue-specific changes than those involved
with the general cell cycle. Given the scope of long-term
anatomical changes and the large number of differentially
expressed transcripts, the transcriptional machinery itself is
likely to become dysregulated as chronic pain progresses.
Within upregulated transcriptional networks, we identified
pathways that were relevant to cellular growth, differentiation,
structural function and neuronal function (Alvarado et al.,
2013). This is important since pain-related structural and
functional changes may involve several of these pathways in
degenerative/regenerative changes in the cortex due to altered
neuronal/dendritic architecture (Freeman et al., 2008), glial loss
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or modifications to the extracellular environment (Tajerian and
Clark, 2015).
Within the differentially expressed transcripts associated
with nerve injury, one third were annotated proteincoding transcripts, and the remaining were an assortment
of non-coding RNAs of various identities (lincRNAs,
miRNAs, etc.). These data offers additional insight into
the function of previously uncharacterized transcripts that
do not code for protein. Thus, non-coding RNAs within
the PFC may also play a role in neuropathic pain. Our
transcriptome analysis also revealed enrichment of nonannotated transcripts derived from within and outside of
gene bodies (non-annotated in mm9 genome assembly)
(Alvarado et al., 2013). While little is known regarding their
function, reports suggest that non-coding RNAs within
specific cell types and neuroanatomical structures may be
artifacts of chromatin remodeling (Mercer et al., 2008). Specific
examples of non-coding RNAs have also been shown to
mediate antisense repression in primary afferent neurons
(Zhao et al., 2013) and to act as epigenetic regulators in the
nucleus accumbens in neuropathy (Imai et al., 2011). Given
their diverse functions and origins, more studies and deeper
sequencing are required to reveal a causal role of non-coding
RNAs to chronic pain (Stefani and Slack, 2008; Mercer et al.,
2009).
A growing body of literature using sequencing technology
has revealed transcriptome signatures in illnesses that are
co-morbid with chronic pain in the PFC, including depression
(Sibille et al., 2004), sleep disorders (Maret et al., 2007),
anxiety (Sibille et al., 2004; Virok et al., 2011), and cognitive
impairment (Wood et al., 2013; Humphries and Kohli, 2014).
While geneticists have long sought a heritable mutational
basis for disease susceptibility, genome-wide association
studies and the search for such genes have found few
risk alleles that account for these phenomena in a broader
population (Kraft and Hunter, 2009). In humans, the temporal
transcriptomic architecture of the PFC remains consistent
despite the extensive genetic variability existing in natural
human populations (Colantuoni et al., 2011). Thus, factors that
regulate transcriptional changes from DNA lie ‘‘above’’ genetic
determinants.

Epigenetic Mechanisms and Function in
the Prefrontal Cortex
We propose epigenetic modulation of gene expression as
a mechanism contributing to long-term plasticity in the
nervous system in general and in the PFC specifically in
chronic pain conditions. Epigenetics is a broad term used to
describe modifications to the function of a gene that do not
alter the sequence of a gene itself. In the adult brain, this
definition encompasses stable changes to gene function beyond
those associated with cellular differentiation following somatic
cell division. Epigenetic mechanisms involve transcriptional
regulation through either chromatin modification or through
the covalent modification of the DNA molecule itself. The
addition of a methyl group to the 5’ position of the cytosine
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ring, catalyzed by DNA methyl transferase, DNMT1, has
been reported to interact with transcripts and inhibit the
methylation of particular genomic loci (Di Ruscio et al.,
2013). This is particularly interesting given the abundance
of non-coding RNAs within the brain of injured animals.
Furthermore, the methyl moiety of methylated DNA can be
further modified by hydroxylation (Kriaucionis and Heintz,
2009) and carboxylation catalyzed by TET enzymes (Ito et al.,
2010). More recently, the term ‘‘epigenetics’’ has begun to
incorporate other mechanisms of regulation that function
through higher order chromatin folding (Cremer and Cremer,
2010), non-coding RNAs (Flanagan and Wild, 2007) and
editing of mRNAs. Here we will focus primarily on DNA
methylation as a molecular medium for storing broad, longterm changes in transcription in the PFC in chronic pain
conditions.
Genomic methylation can be distributed within CpG
dinucleotides (Bird, 1986) and non-CpG elements (Ramsahoye
et al., 2000). In the adult mouse brain, 75% of this methylation
occurs within CpG nucleotides (Guo et al., 2013) and in
most tissues, methylation is stable, with only ∼6% variation
in differential methylation between tissues (Lister et al.,
2009; Hon et al., 2013; Ziller et al., 2013). Differential
methylation that occurs within these 6% cytosines can regulate
transcription and splicing through multiple mechanisms. By
regulating which genes are and are not expressed in an
individual cell, DNA methylation allows the same genomic
DNA to encode the multitude of phenotypes in multicellular
organisms which emerge with cellular differentiation, such as
the difference between brain cells and skin cells within the
same individual (Razin and Riggs, 1980). For example, increased
DNA methylation in promoters or enhancers silences their
activity through the recruitment of transcriptional repressors
and/or steric hindrance of methyl groups (Stein et al., 1982;
Comb and Goodman, 1990). In contrast, increases in DNA
methylation within gene bodies are associated with actively
transcribing genes (Lister et al., 2009; Hon et al., 2013).
However, it is unclear whether the methylation in gene bodies
plays a role in regulation of gene expression as most of
the studies documenting this are descriptive and there is no
clear mechanism that links gene body methylation and either
transcription initiation or elongation. It is clear that the issue
of ‘‘gene body methylation’’ requires better biochemistry which
has been completely lacking in the recent flurry of genome
wide mapping studies. Additionally, DNA methylation has
been implicated in regulating alternative splicing in mammals
(Shukla et al., 2011) and invertebrates (Foret et al., 2012) by
pausing transcriptional machinery within stretches of methylated
DNA. Perhaps the only strong evidence to date on the role
of DNA methylation in controlling gene expression comes
from the pioneering studies of Doerfler (Vardimon et al.,
1982) and Razin and Cedar (Stein et al., 1982) from the
early 80 s which showed that promoter methylation completely
silences gene expression of transfected viral and genomic
promoters. These studies have been repeated numerous times
and, without exception, methylation of promoters silences gene
expression. However, the mechanisms have been more difficult
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to understand. There is paucity of biochemical data that truly
examines mechanisms of promoter silencing. The strongest data
comes from pioneering studies in early nineties showing that
binding of transcription factor is inhibited by methylation of
the recognition element g (Comb and Goodman, 1990). In
addition to this simple and attractive mechanism, a chromatinbased mechanism was proposed in the late nineties. Bird has
suggested that methylated DNA binding proteins (MBDs; Nan
et al., 1998) recruit complexes such as histone deacetylases
that result in an inactive chromatin structure. However, later
data (Baubec et al., 2013) shed some doubt on this simplistic
understanding of the role of MBDs as they were found to
bind both methylated and unmethylated genes as well as active
and inactive genes. Although MeCP2 was proposed to be a
ubiquitous suppressor of methylated promoters, analysis of gene
expression in MeCP2 knock outs revealed silencing of 85%
of transcripts whose expression was changed and conversely
overexpression of MeCp2 resulted in induction of most genes
that were altered by MeCP2 overexpression (Chahrour et al.,
2008).

Role of DNA Methylation in the Brain:
Learning, Memory and Neurodegenerative
Disease
In the brain, DNA methylation is a dynamic process throughout
the entire life cycle. For example, in the developing mammalian
brain, methylomes of neurons are widely reconfigured during
synaptogenesis (Lister et al., 2013). In adults, DNA methylation
is involved in memory and synaptic plasticity (Miller and
Sweatt, 2007; Day and Sweatt, 2010) possibly through the
regulation of DNMT3A/B in the forebrain (Feng et al.,
2010). These patterns of DNA methylation have elucidated
several molecular signatures underlying mental illness related to
maternal deprivation (Weaver et al., 2004a; Massart et al., 2014b),
depression (McGowan et al., 2009) and sleep disorders (Massart
et al., 2014a).
A causal role between DNA methylation in the brain and
learning and memory is supported by data from contextual
fear learning paradigms showing, for example, aberrant
and reversible methylation of calcineurin and brain derived
neurotropic factor, both known regulators of synaptic plasticity
(Lubin et al., 2008; Miller et al., 2010). In addition, the causal
role of DNA methylating machinery (DNMTs) and their
pharmacological inhibition have been directly linked to several
additional learning paradigms (Miller and Sweatt, 2007; Miller
et al., 2008; Feng et al., 2010; Day et al., 2013). The role of DNA
methylation within the brain has been further extended to the
transduction of epigenetic marks into the germ line and the
transmission of heritable traits related to olfactory behaviors
(Dias and Ressler, 2014). Finally, the role of DNA methylation
in the brain has been extended to pathological mental health
conditions. For instance, in a recent epigenetic-wide association
study in human autopsied brains, the methylation status of
several CpGs was significantly associated with the burden of
Alzheimer’s pathology (De Jager et al., 2014). In schizophrenia,
DNA methylation profiles from the frontal cortex have shown
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aberrant downstream methylation of candidate regulators
of disease pathology (Numata et al., 2014; Walton et al.,
2014).
Hypothesis: Alterations in DNA Methylation in the Prefrontal
Cortex Following Nerve Injury Mediate the Long-Term Genomic
Impact of Pain as a Fundamental Mechanism Contributing
to the Chronicity of Pain. This Mechanism Raises the
Potential of Dna Methylation-Modulating Therapy for Reversing
Chronic Pain.
Our hypothesis underlines the importance of epigenetic
regulation of PFC plasticity in chronic pain (Figure 1).
We have previously reported hypomethylation in the PFC
and amygdala 6 months following peripheral nerve injury
(Tajerian et al., 2013). The amygdala is implicated in fear and
anxiety, modulates the PFC and is modulated by it. Thus,
we hypothesize that chronic pain leaves lasting changes in
DNA methylation that stably alter genomic programming
and could be responsible for pain chronicity and painassociated co-morbidities. We have also previously shown
that housing mice in environments with social and physical
enrichment attenuated nerve injury-related changes in genomic
hypomethylation within the PFC and reduced pain-like
behaviors. We therefore also hypothesize that pain-related
changes in methylation within the PFC are dynamic. While
the changes in global DNA methylation demonstrate a shift
in the DNA modification landscape related to pain-associated
brain plasticity, the impact of altered DNA methylation on
transcriptional regulation of individual genes remains to be
clarified.

Synaptotagmin II: A Proof-of-Principle
Case Study
Our hypothesis predicts that changes in DNA methylation
in promoters and enhancers of individual genes will result
in alterations in gene expression contributing to pain-related
changes in brain structure and function. In order to test
our hypothesis, we selected Synaptotagmin II (syt2) [GenBank:
AL596207.10] as our test case. Syt2, a known regulator of
synaptic function, belongs to a family of membrane-trafficking
proteins, is involved in synaptic vesicle docking and fusion,
and acts as a calcium sensor for fast neurotransmitter release.
Since syt2 was previously shown to be upregulated in the PFC
of neuropathic mice 6 months after injury (Alvarado et al.,
2013), whether this dysregulation is under epigenetic control
was investigated. To identify the 5’ regulatory regions of the
gene we utilized previously deciphered whole epigenome map
of regulatory regions in the mouse genome (ENCODE Project
Consortium, 2011) to identify areas of the gene with promoterlike activity. A H3K4me3 peak (a histone modification which
is a hallmark of promoters) (ENCODE Project Consortium,
2011) was located downstream of the transcription start site of
the gene (see map in Figure 2) and the state of methylation
of this region was mapped in the PFC in nerve injured and
control mice.
Pyrosequencing analysis of the methylation state of 11 CpG
sites residing downstream of the syt2 transcriptional start
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FIGURE 1 | Chronic pain and its tissue specific and cellular effects on the PFC. (A) Overview of neuroanatomical and molecular changes that accompany
pain and illustrations of (B) higher order chromatin folding, (C) histone modification; and (D) DNA modifications.

FIGURE 2 | DNA methylation and transcriptional regulation of the Syt2
Promoter. (A) Physical map of the syt2 regulatory region with predicted
transcription factor binding sites below. (B) Transcription of Syt2 in control and
injured animals n = 6/group. (C) Luciferase promoter assay of the syt2 promoter
cloned into pCpGl in antisense, sense, and methylated sense directions.

site (TSS; Figure 2A) showed significant hypomethylation in
the nerve injured group compared to controls (Figure 2B,
n = 6/group). In order to directly determine whether methylation
of CG sites in this syt2 regulatory region affects the ability of this
region to activate transcription, the region was subcloned into a
CpG-deficient luciferase reporter; the same region was subcloned
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Transcription in the sense direction is blocked by methylation of the syn2
promoter n = 3/group. (D) Bisulfite methylation mapping of the putative syt2
promoter upstream of the syt2 transcriptional start site (TSS) demonstrating
neuropathy-induced decreases in DNA methylation at multiple sites
* = p < 0.05, ** = p < 0.005, *** = p < 0.001. Error bars = SEM.

in the antisense direction as a negative control. The promoter
was then methylated in vitro using Sss1 DNA methyltransferase
or mock methylation was performed in absence of enzyme as
a negative control. Since the vector does not contain CG sites,
only CG sites in the inserted syt2 region could be methylated
in vitro. The mock methylated and methylated syt2 luciferase
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reporters were transiently transfected into HEK293 cells. The
luciferase assay results demonstrated that this syt2 region directs
transcriptional activity that is inhibited by the same methylation
of CG sites that are differentially methylated in vivo in response
to nerve injury (Figure 2C, n = 3/group). Interestingly, we
observe changes in DNA methylation in a very limited area in
the promoter. This is consistent with the hypothesis that DNA
methylation silences promoter activity through interference with
binding of factors discussed above. For example, we have shown
previously that epigenetic programming by maternal care of the
Glucocorticoid receptor gene involves site specific changes in one
CG which is also the binding site for the transcription factor
NGFI-A (Weaver et al., 2004a). We showed that methylation of
the NGFI-A binding site inhibits NGFI-A binding and silences
promoter activity (Weaver et al., 2007). Further, experiments are
required to identify the transcription factor that is inhibited by
DNA methylation in the syt2 promoter.
Examination of syt2 methylation in animals that were
subjected to nerve injury provides evidence in support of the
hypothesis that DNA methylation regulates gene expression
within the PFC in chronic pain. These changes were observed
in the brain long after the original peripheral injury. Thus,
our data provides a proof of principle for DNA methylation of
regulatory regions as a mechanism for long-term reprogramming
of gene expression in response to peripheral nerve injury. Further
experiments are required to determine the full importance
of this mechanism in reprogramming gene expression in the
central nervous system following a chronic pain-producing
injury.
Syt2 expression is critical for synaptic transmission in
caudal and forebrain regions (Pang et al., 2006; Kochubey
and Schneggenburger, 2011). In general, synaptotagmin is a
marker of synaptic density and plasticity and its increase is
correlated with synaptogenesis (Masliah and Terry, 1993). Our
data are consistent with previous findings showing increased
syt2 expression in the PFC of rats subjected to chronic restraint
stress (Virok et al., 2011), supporting the hypothesis that chronic
anxiety/stress (regardless if its source being chronic restraint
or chronic pain) could result in profound changes in synaptic
structure and/or function.

Epigenetics of Chronic Pain: Current
Understanding and Future Directions
While the role of DNA methylation in regulating transcription
has been extensively validated, we are only beginning to
understand its full effects on a genomic landscape. For example,
DNA methylation within the PFC following nerve injury
decreased by 12%, accounting for ∼180,000 CpG sites across the
genome (Tajerian et al., 2013). A 12% decrease in methylation
relating directly to transcripts within the genome would reflect
a dramatic effect on the transcriptome. However, we only
observed a change of 800 protein coding transcripts considering
>1.5% of our genome codes for protein (Lander et al., 2001).
Furthermore this observation does not account for cytosine
methylation that occurs outside of a CpG dinucleotide that has
been considered to be more widely distributed within the brain
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(Lister et al., 2013). This supports additional roles for DNA
methylation and their relation to chromosomal integrity (Eden
et al., 2003) and higher order chromatin structure (JimenezUseche et al., 2013). For example, telomeric and centromeric
repeats are CpG-dense and heavily methylated in post-mitotic
cells (Yoder et al., 1997; Han et al., 2008). Increased methylation
at these sites would involve condensation of chromatin and
increased stability of higher order structures. We speculate
that such hypomethylation would also implicate repetitive
elements within the genome such as SINE/LINE transposable
elements, also shown to affect nuclear structure by defining
chromosomal breaking points as seen in immunodeficiency
disorders (Tuck-Muller et al., 2000). Our promoter analysis
(Table 1) and differential transcriptome, shows a depletion
of weak promoters (CpG island rich). This suggests that the
protein-coding component of our data may rely on the DNA
methylation of CpG island poor promoters (narrow- and broadtype promoters). As a result this extends our interpretation of
genomic hypermethylation outside of the scope of protein coding
genes. Our interpretation of genomic hypomethylation is limited
by our approach using a restriction enzyme-coupled assay and
not a comprehensive view of which genomic areas become
hypomethylated in pain. Future studies using approaches such
as methylated DNA immunoprecipitation and sequencing will
offer the necessary resolution needed to reveal the nature of DNA
methylation associated with pain.
The data collected thus far is limited to a single time point
6 months post-injury. It will be important to gain a temporal
understanding of pain-related changes in DNA methylation.
Future studies should examine that time course of changes
within the brain. Are there wide-spread changes in methylation
throughout the CNS one day after an injury? One month?
Three months? Exactly what genes are dysregulated at each of
these time points? Do these changes precede the development of
cognitive or emotional changes or vice versa?
Given the magnitude of the pain-related changes in global
methylation, it was surprising that no changes were observed
in any of the known regulators of methylation (i.e., DNMTs,
methylated DNA binding proteins) in our transcriptomic
screen of the PFC. Is this because massive dysregulation of
hypermethylation/hypomethylation through the DMNTs occurs
early after injury but by 6 months has reached a new steady
state? Given the chronicity of pain and its co-morbidities, we
believe that the processes underlying neuroplasticity are part of
the etiology of the disease and exist in a continuum of cause and
effect. For example, while co-morbidities of chronic pain may
not manifest themselves early following injury, the emergence of
co-morbidities may initiate a cascade of transcriptional changes
in the brain that program long-term changes. This cascade,
modulated by DNA methylation and other epigenetic processes
over the course of months to years, may feed into the pathology
of chronic pain, thus increasing the burden of the disease. Would
that imply that pain-related changes in methylation are more
difficult to reverse months vs. days after injury? All of these
questions merit further exploration. However, it should be noted
that DNA methylation states of genes are regulated by many
factors in addition to global levels of enzyme such as local
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presence of transcription factors and chromatin states of genomic
loci, these rather than global changes in enzyme levels might be
the determining causal agents of changes in DNA methylation in
chronic pain.
Interpretation of changes of DNA methylation in the brain, as
compared to other tissues, is complicated by cell heterogeneity.
In the brain, it is difficult to attribute altered patterns of
methylation to specific cell types. In Lister et al., mapping of
the brain methylome, cell sorting enabled distinction between
neurons compared to astrocytes (Lister et al., 2013). However,
there is still extensive heterogeneity of neuronal cell types even
within a single brain region. This is particularly important
given that neurons within the PFC have more inter-individual
variability in DNA methylation than do other cell types within
the same tissue (Iwamoto et al., 2011). The difficulties in
interpreting these changes are obvious when one considers a
hypothetical brain region where there is 0% methylation at all
glia-specific alleles and 100% methylation at all neuronal specific
alleles, resulting in an observation that ∼50% methylation.
Future studies examining the contributions of different neuronal
and non-neuronal cells using either cell sorting or histological
methods are needed to begin to unravel these complexities.
It is important to note that epigenetic changes are not
independent of one another. A great deal of crosstalk between
DNA methylation has been reported (D’Alessio et al., 2007; Ou
et al., 2007; Brinkman et al., 2012). It is therefore important
to examine additional layers of epigenetic regulation. This
additional tier of regulation may hold clues into the mechanisms
of chronicity, specifically regarding the expression of specific
gene families.
Finally, while this manuscript uses the example of syn2 to
illustrate the main hypothesis, the role of individual genes or
gene families is virtually unexplored. While some differentially
methylated sites may be critically important in pain-related
neuroplasticity, it is likely that many are not. Understanding
epigenetic regulation at both the genome-wide and the genespecific levels will provide insights into how chronic pain changes
the brain and how to reverse it.

Epigenetics of Chronic Pain: Potential
Therapeutic Targets
One fundamental difference between epigenetic regulation and
genetic polymorphisms is the potential of the former to be
modulated by pharmacological manipulations (Szyf, 1994, 2009).
In rodents, the behavioral impact of early life experience
(i.e., maternal care) is reversible in the adult offspring with
epigenetic drugs (Weaver et al., 2004a,b, 2005, 2006). The
potential therapeutic value of interventions targeting epigenetic
mechanisms underlying chronic pain has exciting clinical
significance.
To date, most pharmacological interventions directly
targeting epigenetic mechanisms have been used to provide
evidence of epigenetic involvement rather than to explore viable
treatment options. However, with the increased emphasis on
pain epigenetics, it is plausible that more targeted approaches
could be applied to the treatment of pain and its related
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comorbidities at the peripheral, spinal, and supraspinal levels.
Currently, small molecule drugs targeting epigenetic machinery
function globally, modifying the genome across multiple cells
and tissues. Appropriate targeting of epigenetic therapeutics is
needed to enhance specificity and reduce systemic side-effects.
This targeting can be tissue-, cell- or gene-specific. Although
this statement reflects common wisdom that good agents
should be ‘‘magic bullets’’ it isn’t clear that ‘‘dirty’’ drugs will
not have a therapeutic value. It is possible that general DNA
methylation inhibitors such as RG108 (Machnes et al., 2013)
or methyl donors such as SAM (Fuso et al., 2011) or general
HDAC inhibitors such as SAHA (Hahnen et al., 2006) would be
effective in treating chronic pain with the appropriate dosing
and scheduling. Moreover, since DNA methylation associated
with chronic pain appear to be widespread, it is possible that
general modulators of DNA methylation that act system-wide
will be required.
Although gene-targeting DNA methylation modifiers are still
only a hypothetical approach, of potential therapeutic value
might be gene-specific epigenetic targeting through recently
developed genome editing technology. For example, TET-TALE
fusion proteins have been shown to effectively target and
demethylate individual genes in vitro (Maeder et al., 2013)
and the recent development of Cas9 systems offer novel and
flexible approaches to individual gene targeting (Hsu et al.,
2014). While these approaches offer ∼20--100 bp resolution, their
development remains in its infancy and they have only been
developed as tools for research.
The therapeutic interventions currently thought to offer some
benefits through DNA methylation exist include nutritional
inputs such as folate and other methyl donor intermediates.
Relevant to neuropathy, folate has been shown to aide axonal
regeneration in a dose-dependent manner through DNA
methylation machinery and folate metabolism (Iskandar et al.,
2010). Similarly, other methyl donors such as dietary choline are
critical for fetal hippocampal brain development via genomic and
gene-specific DNA methylation patterns (Niculescu et al., 2006).

Concluding Remarks
Despite its high prevalence, little is known about the brain
mechanisms underlying chronic pain and its associated comorbidities. This hypothesis paper builds upon previous
publications where we propose that DNA methylation
contributes to the chronic changes in behavior and gene
expression in neuropathic mice. Furthermore, it provides proof
of principle evidence for linking peripheral injury-triggered
central changes in DNA methylation and transcriptional
regulation. Finally, we propose that long-term alterations in
DNA methylation could provide a molecular substrate for
chronic pain-related changes in the CNS, forming a ‘‘memory
trace’’ for pain in the brain.
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